EUCTR2011-006100-12-ES
Active, not recruiting
Not Applicable
Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) for patients with Fanconi Anemia Subtype A. - Fancolen-1
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS0 sites5 target enrollmentJanuary 27, 2012
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS
- Enrollment
- 5
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patients diagnosed with the Fanconi anemia complementation group\-A
- •\- At least one of the following parameters must be less than the indicated values?: hemoglobin 8\.0 g / dL, neutrophil count: 750/mm3, platelets: 30\.000/mm3
- •\- Age\> 1 year
- •\- Lansky Index\> 60%
- •\- Mild functional impairment of organs
- •\- To provide informed consent in accordance with current legislation
- •\- Number of transduced CD34\+ cells: At least 3x100000 purified CD34 \+ / kg body weight
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •\- Patients with HLA\-identical family donor.
- •\- Evidence of leukemia or myelodysplastic syndrome, or cytogenetic abnormalities in bone marrow aspirates predictive of those. In this case studies performed two months before the entry of the patient in the clinical trial will be considered as valid
- •\- Evidence that the patient has signs of somatic mosaicism associated to hematologic improvement.
- •\- Any concomitant disease or condition in the investigator's opinion incapacitate the subject for their participation in the study.
- •\- Effect on pre\-existing sensory or motor\> \= grade 2 according to the criteria of the National Cancer Institute (NCI).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Safety assessment and dose of fibrin sealant derived from snake venom in the treatment of wounds.RBR-9mbdj3Faculdade de Medicina de Botucatu - Unesp
Not yet recruiting
Phase 1
CIGB-Mambisa/Abdala in convalescentsCOVID-19 ConvalescenceCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000382Center for Genetic Engineering and Biotechnology (CIGB)120
Active, not recruiting
Phase 1
Clinical trial evaluating the safety, neutralizing capacity and the lowest effective dose for antivenom treatment of multiple Africanized bees stings Apis melliferaRBR-3fthf8Faculdade de Medicina de Botucatu
Recruiting
Phase 1
Phase I/IIa trial of Ga-68 PSMA-11 produced on the MPS200 PSMA-Ga automated synthesizerJPRN-jRCT2022230014Shiga Tohru9
Active, not recruiting
Phase 1
VAC079; a study to the assess the safety and efficacy of the malaria vaccine PvDBPII in Matrix M1EUCTR2019-002872-14-GBniversity of Oxford / Clinical Trials and Research Governance24